160 HEALTH (02656) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 652 million yuan, representing a 5% year-on-year increase. The loss attributable to company owners was 72.986 million yuan, narrowing by 32.22% compared to the previous year. The loss per share was 0.24 yuan. According to the announcement, the revenue growth was primarily driven by strong performance in the company's digital healthcare solutions and pharmaceutical health product sales.